Magnesium Sulfate Versus Ipratropuim Bromide in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
COPD Exacerbation
Interventions
DRUG

Ipratropium bromide

Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.

DRUG

Magnesium Sulfate

Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.

Trial Locations (2)

5000

University Hospital of Monastir, Monastir

5100

Soudani Marghli, Mahdia

All Listed Sponsors
lead

University of Monastir

OTHER

NCT01136421 - Magnesium Sulfate Versus Ipratropuim Bromide in Acute Exacerbation of Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter